Meadowbrook Advisors Group LLC Buys Shares of 3,695 Astrazeneca Plc $AZN

Meadowbrook Advisors Group LLC bought a new position in Astrazeneca Plc (NYSE:AZN) in the 4th quarter, HoldingsChannel reports. The fund bought 3,695 shares of the company’s stock, valued at approximately $648,000.

Several other large investors also recently made changes to their positions in the company. IHT Wealth Management LLC raised its holdings in shares of Astrazeneca by 0.3% during the fourth quarter. IHT Wealth Management LLC now owns 17,527 shares of the company’s stock valued at $3,076,000 after buying an additional 54 shares during the last quarter. Visionary Wealth Advisors grew its holdings in Astrazeneca by 1.5% in the 4th quarter. Visionary Wealth Advisors now owns 4,197 shares of the company’s stock worth $737,000 after buying an additional 60 shares in the last quarter. Vista Investment Management increased its position in Astrazeneca by 0.3% in the 4th quarter. Vista Investment Management now owns 21,215 shares of the company’s stock valued at $3,723,000 after acquiring an additional 60 shares during the period. Kestra Investment Management LLC increased its position in Astrazeneca by 1.9% in the 4th quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock valued at $595,000 after acquiring an additional 63 shares during the period. Finally, Luken Investment Analytics LLC increased its position in Astrazeneca by 4.3% in the 4th quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock valued at $274,000 after acquiring an additional 64 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on AZN shares. UBS Group reiterated a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 9th. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Finally, Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Price Performance

Shares of NYSE:AZN opened at $174.87 on Friday. The stock has a market cap of $271.20 billion, a price-to-earnings ratio of 26.26, a PEG ratio of 1.52 and a beta of 0.25. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. Astrazeneca Plc has a 12 month low of $137.23 and a 12 month high of $212.71. The stock’s 50 day moving average price is $186.62 and its 200 day moving average price is $186.27.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The firm had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. Equities research analysts anticipate that Astrazeneca Plc will post 9.39 earnings per share for the current fiscal year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.